CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
NCT ID: NCT02189629
Last Updated: 2019-11-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
453 participants
INTERVENTIONAL
2015-02-23
2017-02-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris
NCT02556788
Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris
NCT02566369
Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris
NCT03915860
Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation
NCT04856904
Dose Range Study of CD5789 in Acne Vulgaris
NCT01616654
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CD5789 (trifarotene) cream
CD5789 (trifarotene)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CD5789 (trifarotene)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The Subject has a minimum of 20 inflammatory lesions and 25 non-inflammatory lesions at Screening and Baseline visits on the face.
Exclusion Criteria
* The Subject has more than 1 nodule on the face at Screening and at Baseline visits.
* The Subject has any acne cyst on the face at Screening and at Baseline visits.
9 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Galderma R&D
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kevin Chan
Role: STUDY_DIRECTOR
Galderma R&D
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Galderma Investigational Site
Mobile, Alabama, United States
Galderma Investigational Site
Rogers, Arkansas, United States
Galderma Investigational Site
Sacramento, California, United States
Galderma Investigational Site
San Diego, California, United States
Galderma Investigational Site
Miami, Florida, United States
Galderma Investigational Site
Miramar, Florida, United States
Galderma Investigational Site
Newnan, Georgia, United States
Galderma Investigational Site
Louisville, Kentucky, United States
Galderma Investigational Site
Albuquerque, New Mexico, United States
Galderma Investigational Site
New York, New York, United States
Galderma Investigational Site
High Point, North Carolina, United States
Galderma Investigational Site
Beachwood, Ohio, United States
Galderma Investigational Site
Portland, Oregon, United States
Galderma Investigational Site
Knoxville, Tennessee, United States
Galderma Investigational Site
Chomutov, , Czechia
Galderma Investigational site
Hradec Králové, , Czechia
Galderma Investigational Site
Olomouc, , Czechia
Galderma Investigational Site
Pardubice, , Czechia
Galderma Investigational site
Prague, , Czechia
Galderma Investigational Site
Augsburg, , Germany
Galderma Investigational Site
Berlin, , Germany
Galderma Investigational Site
Berlin, , Germany
Galderma Investigational Site
Dessau, , Germany
Galderma Investigational Site
Mahlow, , Germany
Galderma Investigational Site
Münster, , Germany
Galderma Investigational Site
Wuppertal, , Germany
Galderma Investigational Site
Balatonfüred, , Hungary
Galderma Investigational Site
Miskolc, , Hungary
Galderma Investigational Site
Pécel, , Hungary
Galderma Investigational Site
Szeged, , Hungary
Galderma Investigational Site
Szekszárd, , Hungary
Galderma Investigational Site
Szolnok, , Hungary
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RD.06.SPR.18250
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.